Localization and Function of Cat Carotid Body Nicotinic Receptors

B. DINGER, C. GONZALEZ*, K. YOSHIZAKI** and S. FIDONE
Department of Physiology, University of Utah School of Medicine, Salt Lake City, UT 84108 (U.S.A.)
(Accepted October 23rd, 1984)

Key words: acetylcholine -- a-bungarotoxin -- autoradiography -- carotid body -- dopamine release -- nicotinic receptors

Acetylcholine and nicotinic agents excite cat carotid body chemoreceptors and modify their response to natural stimuli. The present experiments utilized [125I]a-bungarotoxin ([125I]a-BGT) to localize within the chemosensory tissue the possible sites of action of exogenous and endogenous nicotinic cholinergic substances. In vitro equilibrium binding studies of intact carotid bodies determined a $K_d$ of 5.57 nM and a $B_{max}$ of 9.21 pmol/g of tissue. Chronic section (12-15 days) of the carotid sinus nerve (CSN) did not change the amount of displaceable toxin binding. In contrast, the specific binding was reduced by 46% following removal of the superior cervical ganglion. Light microscope autoradiography of normal, CSN-denervated and sympathectomized carotid bodies revealed displaceable binding sites concentrated in lobules of type I and type II cells. Treatment of carotid bodies with 50 nM a-BGT in vitro reduced by 50% the release of [3H]dopamine (synthesized from [3H]tyrosine) caused by hypoxia or nicotine, and also significantly reduced the stimulus-evoked discharges recorded from the CSN. The data suggest (1) an absence of a-BGT binding sites on the afferent terminals of the CSN and (2) that nicotinic receptors located within parenchymal cell lobules may modulate the release of catecholamines from these cells.

INTRODUCTION

The carotid body is an arterial chemosensory organ whose parenchyma consists of two distinct cell types in close association with a dense capillary network. Type I (glomus) cells possess abundant dense and clear cored synaptic vesicles, mitochondria and a highly conspicuous rough endoplasmic reticulum. Specialized terminals formed by afferent fibers from the carotid sinus nerve (CSN) synaptically appose the type I cells while slender cytoplasmic processes of type II cells, whose cytology resembles Schwann cells, envelop the afferent terminal-glomus cell complex.

In 1936, Heymans et al. 34 were the first to observe that small intracarotid doses of acetylcholine (ACh) stimulated respiration in a manner similar to natural stimulation of the carotid body. In the ensuing decades, numerous studies investigated the role of ACh in chemosensation and demonstrated that small quantities of cholinergic agonists and antagonists profoundly altered chemoreceptor discharge 20. Neurochemical investigations indicated that the metabolic machinery necessary for ACh synthesis, storage and inactivation appear to be associated with type I cells in the carotid body2,3,23,24,31,35,36 and that afferent fibers of the CSN are nearly devoid of cholinergic activity23,28. In addition, it has been demonstrated that an ACh-like substance is released upon stimulation of the organ in vitro 17,18.

While these data support the notion that ACh may play a role in carotid body chemoreception, the precise actions of this substance in the sensory process has been elusive, particularly with respect to its putative action as a mediator or transmitter of chemosensory information from the type I cells to the afferent fibers of the CSN. Disagreement about the function of ACh stems from the observations that (1) anticho-
linergic agents completely block the effects of exogenously applied ACh, but not the response to natural stimuli\(^{43,45,51}\) (but see also ref. 49); and (2) exogenous ACh enhances chemosensory discharge in the cat\(^{17,22}\) while similar doses in the rabbit produce inhibition of discharge\(^{13,46}\).

A fundamental problem regarding the actions of ACh in the carotid body has been the uncertainty about the locus of its specific effects on type I cells vs afferent nerve terminals. Previous attempts to demonstrate pharmacologically the chemosensory involvement of ACh have not been convincing, since neither the sites of action of the applied drugs, nor the nicotinic vs muscarinic nature of the cholinergic receptors were clearly differentiated. In the present study, we have set out to characterize and localize nicotinic receptors in the cat carotid body using the labeled nicotinic antagonist, \([\text{125}I]\)\(\alpha\)-bungarotoxin (\([\text{125}I]\)\(\alpha\)-BGT). We describe here the equilibrium kinetics of toxin binding in normal cat carotid body, and the use of autoradiographic and biochemical techniques to assay toxin binding following chronic section of the CSN or removal of the superior cervical ganglion. In addition, the results of physiological and pharmacological experiments indicate a functional role for nicotinic receptors in modulating the release of catecholamines from type I cells. A preliminary report of these findings has already been published\(^{12}\).

**MATERIALS AND METHODS**

Three groups of adult domestic cats of both sexes weighing 2.5–4.0 kg were used in this study. In one group, the CSNs were bilaterally resected 12–15 days prior to the binding assay. In a second group, the superior cervical ganglia, which provide the sympathetic innervation to the carotid body vasculature, were surgically removed also at 12–15 days prior to the binding assay. All surgical resection procedures were performed aseptically under pentobarbital anesthesia. A third group of cats consisted of normal unoperated animals.

**Binding assay**

Carotid bodies were removed from anesthetized animals and cleaned of surrounding connective tissue in a lucite chamber filled with \(O_2\)-equilibrated, modified Tyrode’s solution (mM: NaCl 112, KCl 4.7, CaCl\(_2\) 2.2, MgCl\(_2\) 1.1, Na glutamate 42, HEPES 5; pH 7.43 at 37 °C). Wet weight was determined on a Cahn electrobalance fitted with a humidified chamber to prevent drying of the tissues. Tissue samples were placed in vials containing 1.5 ml of \(O_2\)-Tyrode’s solution plus 1% bovine serum albumin, and were preincubated in a waterbath shaker at 37 °C in the presence or absence of either D-tubocurarine (D-TC: 10\(^{-6}\) to 10\(^{-3}\) M; Sigma), or ACh (10\(^{-6}\) to 10\(^{-3}\) M; Sigma) plus eserine (10\(^{-5}\) M; Sigma). Following 20 min of preincubation, \([\text{125}I]\)\(\alpha\)-BGT (spec. act. 138 Ci/mmol, New England Nuclear) was added to the vials to reach final concentrations of from 1.0 to 45.0 nM. Incubation continued at 37 °C, after which the tissues were washed in 10 ml of ice-cold Tyrode’s solution. For biochemical analyses, tissue samples were digested for 4 h at 60 °C in a mixture of 200 \(\mu\)l NCS (Amersham) and 50 \(\mu\)l water. Prior to counting in a liquid scintillation spectrometer, the digestion mixture was neutralized with 750 \(\mu\)l of acetic acid (1.3%), and 15 ml of counting cocktail (PCSII, Amersham) were added to each vial. Specific binding was defined as the binding in the absence of either D-TC or ACh, less the binding in the presence of these substances. The data are expressed as pmol radiolabeled-ligand bound/g of tissue (± S.E.M.), and evaluated using Student’s \(t\)-test.

**Autoradiography**

\([\text{125}I]\)\(\alpha\)-BGT tissue samples for autoradiography were removed from the wash media, immersed in a 0.1 M phosphate-buffered fixative (pH 7.6) containing 1% glutaraldehyde, 1% paraformaldehyde and 0.01 M CaCl\(_2\), and then postfixed in buffered 2% osmic acid solution, dehydrated in ethanol, and embedded in Epon. Semithin sections were cut, mounted on glass slides and coated with Kodak NTB-2 emulsion using a constant rate withdrawal apparatus (48 mm/min). Autoradiographs were exposed for 6-7 weeks, developed in Dektol, and stained with methylene blue.

**Release studies**

The effects of \(\alpha\)-BGT on the release of \([3H]\)dopamine and CSN discharge were determined according to previously published methods\(^{21}\). Briefly summarized, the carotid body was incubated for 2–4 h in
40 μM [3H]tyrosine (spec. act. 20–40 Ci/mmol), after which the organ was mounted in a tiny platinum wire basket suspended within a closed, temperature- and humidity-controlled chamber. The CSN was drawn up into an adjacent suction-type electrode. With the preparation in place, the carotid body was directly beneath an array of 22-gauge hypodermic needles which were connected through roller-type pumps (Technicon) to reservoirs containing unlabelled modified Tyrode solution. The solutions were pre-heated and gas-equilibrated in the reservoirs; final heating of the solutions to 37 °C was accomplished with a servo-controlled heating system. The temperature of the drop surrounding the carotid body was directly monitored through a second thermistor which was positioned to abut against the basket. The relative humidity in the chamber was maintained at 100% by a constant flow of gas, saturated with water vapor. This apparatus permitted a choice of 4 solutions, and the same gas was used to humidify the chamber and to equilibrate the chosen solution. Under control conditions the superfusate was equilibrated with 100% O₂, while stimulus solutions included 10⁻⁵ M nicotine (equilibrated with 100% O₂), or superfusate equilibrated with 30% O₂. The drop rate from the needles was controlled by the speed of the pump, and the precise number of drops that fell from the carotid body was monitored by means of photocells mounted in the opening at the bottom of the chamber. The volumes of superfusate per collection period varied less than 5%. The superfusion rate in all experiments was 0.4 ml/min and was established in preliminary experiments which assessed the viability of the preparation, judged on the basis of a stable chemoreceptor response over a 5 h superfusion period.

The action potentials from the CSN nerve were led through an AC-coupled preamplifier to an oscilloscope and a magnetic tape recorder. The amplified signals were also led through a window discriminator to (1) a frequency-to-voltage converter for final display of the spontaneous neural activity on a chart recorder and (2) a digital counter-printer which read the total number of nerve impulses recorded during the collection period.

The superfusates were collected in vials containing a carrier solution consisting of 0.3 M acetic acid, 1 mM ascorbic acid and 100 μM unlabeled DA, at a final pH of 3.6. The solutions were processed with the alumina adsorption method for recovery of [3H]catecholamines, as described by Crout. After elution of [3H]DA with 0.3 M acetic acid (recovery 65 ± 5%), further elution with 1 M HCl permitted the recovery of dihydroxyphenyl acetic acid (DOPAC), the principal DA catabolite in the carotid body. The eluate of 0.3 M acetic acid was further analyzed using high-voltage paper electrophoresis; the eluate containing [3H]DOPAC was directly counted in a liquid scintillation spectrometer. [3H]DA release is expressed as the sum of [3H]DA and [3H]DOPAC.

RESULTS

Washout and time course

Our initial experiments were designed to determine whether prolonged washing would dissociate significant amounts of bound [¹²⁵I]α-BGT from intact (non-homogenized) samples of carotid body tissue. Carotid bodies were incubated for 3 h in 100 nM [¹²⁵I]α-BGT in the absence of D-TC or ACh. The tissue was then transferred to wash vials containing 10 ml of ice-cold Tyrode's solution. After 20 h of washing, the level of toxin binding was indistinguishable from that present after 1, 2 or 6 h of washing. All subsequent experiments utilized a 1 h wash period. Under these conditions, non-specific binding never exceeded 35% of total binding in the normal carotid body.

The time course of [¹²⁵I]α-BGT binding is shown in
Concentration dependence and inhibition of binding

Equilibrium kinetic studies of \([^{125}I]a\)-BGT binding in normal cat carotid bodies demonstrated a saturable component which was displaceable by \(10^{-3}\) M ACh (Fig. 2A) or D-TC. Specific binding plateaued at concentrations above 11.25 nM toxin. The specific binding data in the figure are fit to a rectangular hyperbola by a 'best-fit' computer method. Non-specific binding appeared to be linear throughout the concentration range and never exceeded 27% of total binding.

The linear Scatchard analysis presented in Fig. 2B indicates a single population of binding sites with a \(K_d\) of 5.57 nM and a \(B_{\text{max}}\) of 9.21 pmol/g of tissue \((r = 0.951, P < 0.01)\). The Hill coefficient of the data is 0.876, suggesting non-cooperative interaction between labeled toxin and the specific binding sites.

Inhibition studies showed that \([^{125}I]a\)-BGT binding was progressively reduced by increasing concentrations of either D-TC or ACh (Table I). At concentrations between \(10^{-6}\) M and \(10^{-3}\) M, the two drugs were similar in their ability to prevent toxin binding. In the presence of 11.25 nM \([^{125}I]a\)-BGT, millimolar concentrations of D-TC or ACh reduced the amount of bound radioactivity by 90%.

Effects of carotid sinus nerve (CSN) denervation and sympathectomy on \([^{125}I]a\)-BGT binding

CSN-denervated and sympathectomized carotid
Fig. 3. [125I]α-BGT binding in normal, CSN-denervated and sympathectomized (removal of superior cervical ganglion) cat carotid bodies. Note unaltered specific binding with increased non-specific binding 12-15 days following CSN-denervation. Sympathectomy reduced the specific binding by 46%.

bodies were studied to further localize α-BGT binding. It has been shown that degeneration of nerve terminals is complete within 12–15 days following either CSN transection or removal of the superior cervical ganglion33. Type I and type II cells in the cat carotid body appear largely unaffected by either procedure4,33. After CSN denervation, specific [125I]α-BGT binding in cat carotid bodies was unchanged (Fig. 3), suggesting that specific toxin binding sites are not present on CSN afferent fibers or their terminals. Non-specific binding, however, was increased in CSN-denervated carotid bodies. The reasons for this finding are not apparent, but may be related to the Schwann cell proliferation which has been shown to accompany nerve degeneration1.

The carotid body is innervated by sympathetic axons arising from the superior cervical ganglion16, and most of these fibers are post-ganglionic axons which terminate on vascular smooth muscle within the organ31. Because presynaptic nicotinic receptors have been demonstrated on the terminals of adrenergic postganglionic neurons37,48, reductions in specific binding were anticipated in sympathectomized preparations. Indeed, our data showed that removal of the superior cervical ganglion resulted in a 46% decrease in specific binding, further suggesting that nicotinic receptors are likely associated with postganglionic sympathetic axons in the carotid body (Fig. 3). Non-specific binding in sympathectomized preparations was similar to that in CSN-denervated animals; i.e. significantly elevated above the levels of non-specific binding found for normally innervated carotid bodies.

** Autoradiographic localization 

To localize specific [125I]α-BGT binding sites in the carotid body, autoradiographic techniques were employed to determine whether significant toxin binding occurred within the lobules of type I and type II cells. As shown in Fig. 4, following incubation in 11.25 nM [125I]α-BGT, the autoradiographic grain distribution in normal (A), CSN-denervated (B) and sympathectomized (C) tissues suggested that the iodinated toxin was concentrated amongst the parenchymal cell lobules. This technique did not permit visualization of small nerve endings (<1.0 μm); nor is the autoradiographic resolution sufficient to differentiate binding on type I vs type II cells. The specific nature of this binding within the parenchymal cell lobules was demonstrated by the absence of silver grains over lobules following incubation in the presence of 10⁻³ M ACh (Fig. 4D).

** Physiological and pharmacological effects of α-BGT 

The effects of α-BGT on chemoreceptor nerve discharge and on endogenous catecholamine release were tested in carotid bodies preloaded with [3H]dopamine ([3H]DA) synthesized from [3H]tyrosine (see Methods). Previous studies in our laboratory have established a proportional relationship between the level of hypoxia and the release of [3H]DA from the carotid body in vitro21. In those studies, [3H]DA release was also correlated with the chemoreceptor discharge recorded from the CSN. In the present experiments, both hypoxia (media equilibrated with 30% O₂), as well as 10⁻⁵ M nicotine were used as stimuli for assessing the effects of α-BGT on transmitter release and nerve discharge.

The carotid bodies with their attached nerves were mounted in the in vitro recording chamber (see Methods), and superfused with 100% O₂-equilibrated media for 30–40 min prior to stimulation. [3H]DA release and CSN discharge were then monitored during sequential 5 min pre-stimulus, stimulus and post-stimulus collection periods, which together comprised a single ‘stimulus cycle’. Twenty minute rest periods (100% O₂ media) separated successive ‘stimulus cycles’. After one hypoxic and one nicotine-
Fig. 4. Light microscope autoradiography of carotid bodies incubated for 30 min in 11.25 nM [125I]-α-BGT. Dark punctate silver grains are localized over lobules of type I and type II cells in normal (A), CSN-denervated (B), and sympathectomized (C) tissue. Silver grains are sparse following incubation in the presence of 10^{-3} M ACh (D). Scale = 10 μm.
stimulus cycle, the preparation was superfused for 1 h with 100% O₂ media containing 50 nM α-BGT, and then re-exposed to each stimulus. The data in Fig. 5 compares [³H]DA release and CSN discharge during control-stimulated vs toxin-stimulated collection periods (expressed as percent control response). Treatment with α-BGT inhibited approximately 50% of the [³H]DA release evoked by hypoxia or nicotine. Significant reductions were also observed in both total and peak CSN discharge. These changes persisted after 2 h of washing, and thus reflected the irreversible binding of α-BGT. These reductions in the response to the stimuli could not have been ascribed to deterioration of the in vitro preparation since previous work in this laboratory has shown that stimulus repetitions over periods of more than 3 h result in slight increases, rather than decreases, in the response ratios.

DISCUSSION

Alpha-bungarotoxin binds nearly irreversibly to postsynaptic nicotinic receptors at mammalian neuromuscular junctions, where it causes prolonged blockage of synaptic transmission. High-affinity components of α-BGT binding have also been described for mammalian central nervous system and sympathetic ganglia. The toxin also blocks synaptic transmission in frog paravertebral ganglia and in the pigeon ciliary ganglion. But in some tissues (e.g. the superior cervical ganglion), α-BGT concentrations which normally saturate the high-affinity sites do not block the effects of endogenous ACh. Thus, the significance of high affinity α-BGT binding is equivocal in the absence of demonstrated physiological, biochemical or behavioral effects.

Our experiments indicate that [¹²⁵I]α-BGT binding in cat carotid body is not unlike its interaction with receptor sites in numerous other tissues. A 5.57 nM $K_d$ is consistent with values established in brain (1.7 nM and 8.0 nM) and autonomic ganglia (~2.0–3.0 nM) and mammalian skeletal muscle (0.37 nM). Moreover, a high-affinity component of toxin binding in the carotid body is incrementally blocked in the presence of increasing concentrations of ACh and D-TC, suggesting that the toxin binds to nicotinic cholinergic sites in this organ. The kinetic data are consistent with the notion that cat carotid bodies contain high affinity α-BGT binding sites similar to those found in skeletal muscle where α-BGT selectively blocks postsynaptic nicotinic receptors.

Our autoradiographic and biochemical studies show that normal and CSN-denervated carotid bodies bind comparable amounts of [¹²⁵I]α-BGT within the lobules of type I and type II cells. The simplest explanation for this finding is that afferent nerve terminals of the CSN do not possess specific nicotinic receptors. However, it must be noted that nerve terminals in the carotid body represent less than 5% of the total tissue volume, and thus reductions in [¹²⁵I]α-BGT binding following denervation may be beyond our assay's limits of detection. An additional factor which might mitigate against detection of nerve terminal receptors is the ability of Schwann cells to bind [¹²⁵I]α-BGT. Since Schwann cells rapidly proliferate during nerve degeneration, and their increased numbers persist for many months following nerve transection, any reductions in toxin binding which correspond to the loss of axons and nerve terminals may be masked by increases in Schwann cell toxin binding. On the other hand, we did observe significant reductions in toxin binding in sympathectomized preparations, where the loss of postganglionic nerve terminals probably represents an equally small volume of carotid body tissue, and where degeneration
is also accompanied by Schwann cell proliferation. Thus, our data suggest that $[^{125}]\alpha$-BGT binding on afferent terminals may be absent, or quantitatively small, and that most of the cholinergic nicotinic receptors within the parenchymal cell lobules are localized to the type I and/or type II cells. Furthermore, the presence of such receptors in the cat carotid body is supported by the findings of Hayashida and Eyzaguirre\(^{30}\), who showed with intracellular recording that small doses of ACh increase the voltage noise and depolarize the type I cells.

Additional evidence for $\alpha$-BGT binding on type I cells has been provided by Chen and Yates\(^{39}\). Their studies with horseradish peroxidase conjugated $\alpha$-BGT revealed binding to a select subpopulation of glomus cells in the rat carotid body. On the basis of dense-cored vesicle measurements, these authors concluded that the cells which bind the toxin correspond to the type B glomus cells identified earlier by MacDonald and Mitchell\(^{10}\). However, in other species, dense-cored vesicle studies have not demonstrated subgroups of glomus cells\(^{53}\). Information on this point is lacking in the cat, and from our data it is not possible to determine whether $\alpha$-BGT binds to a limited glomus cell population.

The effects of $\alpha$-BGT on DA release and chemoreceptor discharge evoked by hypoxia or nicotine confirm the existence of specific nicotinic sites in the cat carotid body and, furthermore, suggest that $\alpha$-BGT blocks receptors which are functionally important for normal chemoreception. In the carotid body, DA is synthesized and released by type I cells\(^{20,21}\) and thus, the ability of $\alpha$-BGT to affect DA outflow, evoked either by hypoxia or nicotine, suggests that cholinergic receptors located on type I cells in cat carotid body modulate the release of catecholamines. Consistent with this interpretation, Hellstrom et al.\(^{12}\) found that depletion of rat carotid body DA by hypoxia was mimicked by methacholine and antagonized by atropine. Studies of transmitter outflow from the corpus striatum\(^{27}\) and hypothalamus\(^{50}\) have likewise revealed nicotinic and muscarinic receptors which, when activated, enhance the release of $[^{3}H]$DA. Hence, the carotid body may utilize a cholinergic-link mechanism to modulate DA release, as has been described for other catecholaminergic systems\(^{59}\).

In summary, a study of the localization and function of $[^{125}]\alpha$-BGT binding in normal and denervated cat carotid bodies indicates that nicotinic cholinergic receptors are located on type I cells (and perhaps type II cells), as well as on post-ganglionic sympathetic nerve terminals. The binding sites on type I/type II cells are characteristically nicotinic and appear to modulate both the release of DA as well as the chemoreceptor discharge. The apparent absence of $[^{125}]\alpha$-BGT binding sites on the CSN suggests that carotid body chemosensation in the cat does not depend upon the activation of cholinergic receptors located on afferent terminals apposed to type I cells.

ACKNOWLEDGEMENTS

The authors wish to thank Ms. Vicki Skelton for skillfully preparing the manuscripts. Research supported by USPHS Grants NS 12636 and NS 07938.

REFERENCES

3 Ballard, K. J. and Jones, J. V., Demonstration of choline acetyltransferase activity in the carotid body of the cat, J. Physiol. (Lond.), 227 (1972) 87–94.
5 Brookes, J. P. and Hall, Z. W., Acetylcholine receptors in normal and denervated rat diaphragm muscle. I. Purification and interaction with $[^{125}]\alpha$-bungarotoxin, Biochemis-
	ry, 14 (1975) 2092–2099.
10 Colquhoun, D. and Rang, H. P., Effects of inhibitors on the


